Regeneron Lays Out Commercial Case For Arcalyst In Gout Flares To Investors; Convincing Payers May Be Challenge
This article was originally published in The Pink Sheet Daily
Executive Summary
During the biopharma's first ever investor day, management outlines early plans for the launch of Arcalyst for the prevention of gout flares.
You may also be interested in...
Regeneron Eyes Another Pipeline Target: Arcalyst In Gout
Fresh from a success with the approval of Eylea for wet AMD, Regeneron has another target in sight: Arcalyst (rilonacept) for prevention of gout flares in patients initiating uric acid lowering therapy. FDA has accepted a supplemental BLA for the drug.
Regeneron Eyes Another Pipeline Target: Arcalyst In Gout
Fresh from a success with the approval of Eylea for wet AMD, Regeneron has another target in sight: Arcalyst (rilonacept) for prevention of gout flares in patients initiating uric acid lowering therapy. FDA has accepted a supplemental BLA for the drug.
Ready To Launch But Nowhere To Go: Regeneron's Eylea Gets FDA Delay
The biotech says it is prepared to launch the wet-AMD drug immediately following FDA approval, which is now expected by Nov. 18.